20 High Growth Mega Cap Stocks You Can Buy And Hold For Next 5 Years

14. AstraZeneca PLC (NASDAQ:AZN) 

AstraZeneca PLC is a biopharmaceutical company that explores, develops, manufactures, and commercializes prescription medicines. It supplies its products and services to specialty and primary care physicians. AZN distributes its products and services through local representative offices and distributors. The company has grown its revenue by 17.77% over the last 5 years.

UBS recently upgraded AstraZeneca from neutral to buy on improving growth prospects:

We like the diversified catalyst path for AZN, no longer dominated by Dato-DXd.

Dato DXd is a treatment for advanced-stage breast cancer and with its approval in January, the company continues to strengthen its portfolio of FDA-approved drugs. AZN estimated annual sales of $5 billion with this particular treatment and that seems to be on target. The company can now focus on the seven high-value drugs it plans to get to the market in 2025. Investors can expect multiple catalysts throughout the year, but due to the nature of drug trials, volatility is expected.